Analyst consensus rating
Pyxis Oncology Analyst Rating: Strong Buy
Direct answer
Pyxis Oncology's consensus rating is Strong Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $8.22.
Forecast evidence checked November 10, 2026.
Get free Pyxis Oncology email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.63
- Average price target
- $8.22
- High price target
- $19.00
- Low price target
- $5.00
- Low target gap
- +206.7%
- Target upside
- +404.4%
- High target gap
- +1,065.6%
- Target range width
- 858.9%
- Consensus rating
- Strong Buy
- Analysts
- 9
- Evidence date
- November 10, 2026
- Valid through
- November 17, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Pyxis Oncology?
Pyxis Oncology has a verified Strong Buy consensus. The same dataset has an average price target of $8.22.
How far are Pyxis Oncology's low and high targets from the recorded price?
The low target implies +206.7%, while the high target implies +1,065.6%.
How many analysts are included in Pyxis Oncology's consensus?
The verified consensus includes 9 analysts.
How is Pyxis Oncology's target upside or downside calculated?
The average target of $8.22 is divided by the recorded price of $1.63, then one is subtracted to produce +404.4%. This does not guarantee a future return.
When was Pyxis Oncology's analyst forecast verified?
The data was verified on 2026-11-10. The dataset is valid through 2026-11-17.